Healthcare Social Media and Updates
Healthcare Social Media and Updates
Healthcare Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
Dramatic increase in autism program utilization in Minnesota. Is this a true increase in autism rates or some other reporting/diagnosis factor or just fraud? Are other states seeing this? (This is not a political question).
While every medical specialty will benefit from digital health and AI, some will especially thrive thanks to these innovations. Here, I listed the top medical specialties with the biggest potential for development in the future. Read on: https://t.co/KhId1Okqf2 https://t.co/rgvsDAjS1q
Clicker training works on orthopaedic surgeons. A study taught surgical skills using a clicker for real-time feedback. 100% of that group nailed every step of a knot tie, vs 33% who learned by demonstration alone.
New: Generate caps a strong month for #biotech IPOs with $400M offering https://t.co/HzslZOPcwM by @gwendolynawu $GENB $AZN $AMGN #IPO
Simple Blood Test For Small RNA Molecules Could Predict Who Is Likely To Live Longer https://t.co/lr59o4Yegp https://t.co/MccF3k72pT
Clinicians know what actions help patients stay healthy. Digital interventions help patients actually take them. Shahid Shah shares more on how CareCognitics is tackling heart failure readmissions: https://t.co/yNe0013amg @CareCognitics #HospitalReadmissions #HITSM https://t.co/SDVIK5m79S
🆕 @ScienceMagazine How gut bacteria interactions [cooperation vs competition, positive vs negative] shape risk for health and disease https://t.co/q8TvbaHDQI https://t.co/kS0S3uUIli
Some hospitals start the SEP-1 bundle early… but ~25% of those patients don’t actually have sepsis. Better prediction could mean fewer unnecessary antibiotics. Learn from Robin Carver: https://t.co/tPRGLQGdIV @PrenosisInc #patientsafety #HITSM https://t.co/CFk7cA5Wib
An Interoperable Vaccine Record: A Roadmap to Realization https://t.co/H1yL7kXH8z #mdpivaccines via @Vaccines_MDPI @HardeepSinghMD @McWilliamsSBMI @HarvardDBMI https://t.co/UCP8IXdHve
What is Infinite Healthcare Worth? As AI becomes a new site of care and automates administrative orchestration, it rapidly eats into $5T+ worth of traditional health care services spend, and potentially represents the biggest market opportunity in all of healthtech....
As national networks mature, the strategy is shifting. Jay Nakashima shares how eHealth Exchange is expanding beyond treatment exchange in 2026. 👀 🔗 https://t.co/uK1RKnn15e @eHealthExchange #QHIN #HITSM https://t.co/7qKBmbZ6FY
What accounts for the progression from healthy aging to Alzheimer's disease over an extended period of time? The critical role of the immune system, particularly T cells and microglia. A new, excellent review @ImmunityCP https://t.co/XqEBcptTuG https://t.co/Xt24BvkDWe
(Hopefully) Final word today on the Makary $QURE (or was it $RGNX) thing: Bottom line: Makary shouldn't be talking publicly about unresolved drug applications. Uniqure doesn't even have an application submitted; and RegenxBio's CRL letter isn't posted to the FDA's...
We'll be gearing up today's webinar on biotech venture capital at the top of the hour. Great guests, great topics. If this is a central issue in your life, tune in. Thousands have signed up already. https://t.co/c16y04mFsD
You've got to watch this Makary interview on CNBC. He attacks a drug, hits the Old FDA and circles all the wagons around Vinay Prasad, who "loves President Trump" and faces a fatwa (WSJ). Makary is getting major props for...
Direct-to-consumer gut microbiome assessments are unreliable, problematic: a review of 7 companies with significant methodologic issues https://t.co/atwmZUNjVE https://t.co/SqlMljuW0y
FDA Commissioner Marty Makary defends rare disease drug rejections, Vinay Prasad "Vinay Prasad is a genius,” Makary said. “He’s on loan from UCSF. He’s published over 500 scientific peer-reviewed articles, and some of the drugs they are criticizing him for...
I've written so much about various details of healthcare's AI revolution that it was time to come up with a high-level overview of what we can certainly expect from AI in the next few years. 10 predictions, coming from four...
Head-to-head trial of the oral GLP-1 drugs in people with T2D. Orforglipron was superior https://t.co/9B7RXIgdJY
$QURE down this morning on comments made by FDA Commissioner Marty Makary to CNBC's Becky Quick. In a discussion about rare-disease drug approvals and Vinay Prasad, Makary said this: "I think there has been a bit of an effort to...
We're making headway for off the shelf preventive cancer vaccines in people with hereditary forms of cancer, e.g. Lynch syndrome https://t.co/F3LqKS46BQ
AI is entering public health infrastructures, connecting epidemiology, clinical data, and research into shared intelligence. When models flag outbreaks early and automate routine tasks, health systems allocate resources with precision and reduce delays. Microblog @antgrasso https://t.co/nuhbxsiFX3
Always fun to look over @JohnCendpts annual list of the top 100 most active VCs in biotech for the past year Top 5, by # of rounds: 1. OrbiMed 2. RA Capital 3. GV 4. General Catalyst 5. Catalio Full list & analysis is live...
$RVMD was collaborating with $TNGX in PRMT5, but now it's working with $BMY (remember that ex MRTX project?). Via @ByMadeleineA @ApexOnco -> https://t.co/mGZjKOiB7p (And $AMGN still dose optimising.)
A meaningful share: AuthorsReading posted an editorial review of The Doctor’s Future. They spotlight the book’s focus on the real-world questions behind AI/robotics in healthcare—privacy, accountability, ethics, patient trust, and how clinicians can adapt their roles with clarity (supported by the...
IEEE has a very technical overview of ingestible electronics and tomorrow's smart pills that could one day deliver drugs and take biopsies. To "take actions based on its findings" is a bit too far-fetched for now. What can these technologies definitely...
I enjoyed working with an all-star team – the great @LisaRotenstein @UCSF and @DBatesSafety of @BrighamWomens – on this paper describing how to measure return on investment (ROI) for clinician-facing AI tools. @JAMAInternalMed https://t.co/uvhb1qI7mG
The combination of GLP-1 drugs (such as Ozempic) and healthy lifestyle factors was associated with less major adverse cardiovascular events in ~100,000 people with T2D @TheLancetEndo https://t.co/phNzEBy7zY https://t.co/DDVi8uedRP
From glucose to vascular health: the future of diabetes care https://t.co/UMhK4BkOE3 #Conditions #Diabetes via @kevinmd
AI isn’t just exposing workflow gaps in healthcare — it’s exposing content fragmentation. The future of clinical AI may depend less on model architecture and more on knowledge integrity. More from @ElsevierConnect at #ViVE2026.👇👇 https://t.co/zbay0c1z1x
Psychedelic tape still trades on vibes > policy. Surgeon General nominee Casey Means says she “would not recommend” psilocybin to the American people today. Yes, she nods to “exciting work” in PTSD and veterans. But that is a far cry from...
The future isn’t just AI scribes — it’s AI across the whole practice. Front desk to billing. Hear Venky Chellappa share @charmhealth's approach at #ViVE2026 👇 https://t.co/Fu8iReWUAZ
When government requirements increase data sharing but systems aren’t connected, the fax machine fills the gap. Jess Czelusniak shares what that reality looked like at VHC Health.👇 Hear more about their experience: https://t.co/D7oXKCb2Kg @VyneMedical @VHCHealth #eFax #HITSM https://t.co/mvrhQyx04R
The @OracleHealth team isn't waiting for the future of healthcare connectivity—we’re setting the standard: https://t.co/Gw7WFnvODg Through this validation program, we’re building trusted relationships with device vendors, streamlining interoperability, and opening the door for continued collaboration and innovation.
An experimental therapy for a rare blood cancer was on the path toward approval by the Food and Drug Administration last year — with internal reviewers recommending it be cleared — before the agency rejected the drug last month, @adamfeuerstein...
Interesting read: the thread and the story. A drug that was approved in Europe in 2022, which looked like it was on track for #FDA approval, instead is rejected. What changed at FDA? 🤔
The Federal Register notice for the (now) March #ACIP meeting is now up & it's ... puzzling. Possible vote on Covid vaccine injury? ACIP can recommend changes to the way a vaccine is used, for safety reasons. But vaccine injuries aren't...
interesting and different efficacy outcomes in ASyS and SSc autoimmune patients treated with blinatumomab (CD3/CD19) and teclistamab (CD3/BCMA), respectively, + Rituximab maintenance. Potential for targeting both BCMA and CD19, especially in ASys. https://t.co/Dyq7h9EeGo
Haha what an original and inspired conspiracy trope. Search my name in CMS Open Payments. I get $0 from pharma companies. ZERO. ZILCH. I do this because I believe in public health and keeping kids from getting serious illnesses. And because, unlike...
A randomized trial of a stem cell therapy vs placebo for aging frailty showed durable and dose-dependent improvement in the 6-minute walk test @CellStemCell https://t.co/2jOYuIgUrY https://t.co/04mEV7OdLo
Online Patient Communities for the E-Patient “Betwixt & Between” a New Pt & an Expert [Aug 29, 2013] @mtmdphd #ASCOConnection https://t.co/IxinXTK715 #mmsm
Identification of Significant Barriers to Accrual (BtA) to @theNCI Sponsored Multiple Myeloma – Clinical Trials (MM-CT): A Step towards Improving Accrual to #ClinicalTrials - @mweissmdphd et al. #ASH12 Abstract 3165 https://t.co/i4zO7ktqHJ #mmsm #caxtx #ctsm
#EAOnc EQUATE EAA181 Effective Quadruplet Utilization After Tx Evaluation: Ph3 RCT NDMM Not Intended for Early ASCT [Activated: 10/27/20] PI= @myelomaMD https://t.co/qD26HMx3J8 #NCT04566328 #mmMRD #mmsm @eaonc @mweissmdphd @VincentRK @LynneWagnerPhD Wei Snyder Kostakoglu @mtmdphd
.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] https://t.co/OizUfJCc2c #mmsm #bmtsm https://t.co/uikUnnJd3n
New @Nature The brains of Super Agers produce more neurons than people some 40 years younger, a neurogenesis resilient signature linked to exceptional cognitive health and memory skills https://t.co/tNB0dTea2F
Guidelines for determination of the number of prior lines of therapy in multiple myeloma [Aug 13, 2015] @VincentRK , Richardson, San Miguel @BloodJournal https://t.co/Tdmr2gTUi6 #mmsm #ctsm #ClinicalTrials https://t.co/ZOobout75Q
Comparative Effectiveness and Safety of PI-Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT-MM Data Analysis [Jan 13, 2026] @NoemiPuigM et al. European Journal of Haematology https://t.co/Vf7USecLlR #NCT02761187 #mmsm #openaccess https://t.co/C5Ya6TTQfo
Assessment of biological age integrating electronic medical records and multi-omics increases accuracy for predicting outcomes @NatureAging https://t.co/7y60SSPTQf https://t.co/u02OlWMdQz
The FT's report on GSK's $950M deal to buy 35Pharma and its pulmonary arterial hypertension drug includes an interesting unnamed insider's quote that new CEO Luke Miels is going after assets where "the science is relatively settled." Maybe leaning into...
Strong claim that needs independent replication: "Our findings provide compelling evidence that circulating smRNAs—especially piRNAs—are powerful predictors of survival in older adults and potential biomarkers of longevity" https://t.co/oi4220zxGY https://t.co/yk3MX4VdQj
